BIAF logo

BIOAFFINITY TECHNOLOGIES INC

BIAFNASDAQ
🏆 #5054 by market capEarnings Nov 12US Equity
$6.78▼ $0.55 (−8.13%)
After hours · at close
🔔
Track BIAF
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 8.1%
7d▼ 21.4%
14d▲ 9.2%
30d▲ 38.4%
ytd▼ 63.5%
1y▼ 87.8%
🏦Market Cap
$53M
Small Cap
📈Revenue Growth (YoY)
-23.2%
Declining
📊Gross Margin
34.6%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
1.6x
Cheap
Otter Score
40
Weak

Trading Snapshot

Day Range
$6.74 – $6.88
52-Week Range
$4.56 – $109.35
Volume
$2.61B
Avg Volume
$1.90B
Shares Outstanding
7.8M
Next Earnings
Nov 15, 2026

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$2M
P/E Ratio
—
P/S Ratio
1.6x
EPS (TTM)
$-6.89
Dividend Yield
—
Dilution (1yr)
+316.7%

Why Investors Own BIAF

  • ✓High-growth profile — revenue up -5.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 48% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BIAF logo

BIOAFFINITY TECHNOLOGIES INC

BIAF
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −34.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
23.2%▼ −35.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▲ +18.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +27.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
115K▲ +316.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$6M YoY
StockOtter · stockotter.space

About BIOAFFINITY TECHNOLOGIES INC

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Mar 2026

Latest News & Updates

🚀
MarketWatch·2h ago

BIOAFFINITY TECHNOLOGIES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift BIAF price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

BIOAFFINITY TECHNOLOGIES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.